Masahiro Miyake1, Kenji Yamashiro2, Yumiko Akagi-Kurashige1, Kyoko Kumagai3, Isao Nakata1, Hideo Nakanishi1, Akio Oishi3, Akitaka Tsujikawa3, Ryo Yamada4, Fumihiko Matsuda4, Nagahisa Yoshimura3. 1. Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan; Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. 2. Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. Electronic address: yamashro@kuhp.kyoto-u.ac.jp. 3. Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan. 4. Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Abstract
PURPOSE: To investigate the association between the vascular endothelial growth factor (VEGF) gene polymorphism and the response to anti-VEGF treatment for choroidal neovascularization (CNV) in highly myopic eyes. DESIGN: Retrospective cohort study. PARTICIPANTS: A total of 357 unrelated highly myopic Japanese patients with axial lengths ≥26.0 mm in both eyes were eligible, and 83 patients who received anti-VEGF therapy for CNV and could be followed for more than 1 year were included. METHODS: We genotyped a functional single nucleotide polymorphism in the VEGF gene, rs2010963. The associations between the distribution of the rs2010963 genotype and the number of eyes with maintained or improved visual acuity (VA) were analyzed. Furthermore, multivariable logistic regression analysis was performed to adjust for 7 possible prognostic factors, including age, sex, CNV size, CNV location, administration of loading dose, pretreatment VA, and number of additional treatments. MAIN OUTCOME MEASURES: The primary end point was maintenance of VA, and secondary end points were progression of chorioretinal atrophy (CRA) and recurrence of CNV. RESULTS: Mean age and mean axial length were not significantly different among 3 genotypes of rs2010963. The percentage of eyes with maintained or improved VA was significantly higher with the G allele of rs2010963 (P =0.016), and stepwise analysis revealed that both rs2010963 and CNV size were associated with VA maintenance (P =0.040 and 0.033, respectively). The secondary analysis revealed that administration of a loading dose was significantly associated with both CRA progression (P =0.031) and recurrence of CNV (P =0.020), whereas rs2010963 was not. CONCLUSIONS: These results suggest that the VEGF polymorphism influences the VA prognosis in highly myopic eyes with CNV within 1 year after anti-VEGF treatment. This association was still observed after removing its confounding effect through CNV size. The rs2010963 polymorphism was not associated with CNV recurrence or CRA progression, which indicates that these changes are not tied to intrinsic factors and may be controllable by improving treatment methods.
PURPOSE: To investigate the association between the vascular endothelial growth factor (VEGF) gene polymorphism and the response to anti-VEGF treatment for choroidal neovascularization (CNV) in highly myopic eyes. DESIGN: Retrospective cohort study. PARTICIPANTS: A total of 357 unrelated highly myopic Japanese patients with axial lengths ≥26.0 mm in both eyes were eligible, and 83 patients who received anti-VEGF therapy for CNV and could be followed for more than 1 year were included. METHODS: We genotyped a functional single nucleotide polymorphism in the VEGF gene, rs2010963. The associations between the distribution of the rs2010963 genotype and the number of eyes with maintained or improved visual acuity (VA) were analyzed. Furthermore, multivariable logistic regression analysis was performed to adjust for 7 possible prognostic factors, including age, sex, CNV size, CNV location, administration of loading dose, pretreatment VA, and number of additional treatments. MAIN OUTCOME MEASURES: The primary end point was maintenance of VA, and secondary end points were progression of chorioretinal atrophy (CRA) and recurrence of CNV. RESULTS: Mean age and mean axial length were not significantly different among 3 genotypes of rs2010963. The percentage of eyes with maintained or improved VA was significantly higher with the G allele of rs2010963 (P =0.016), and stepwise analysis revealed that both rs2010963 and CNV size were associated with VA maintenance (P =0.040 and 0.033, respectively). The secondary analysis revealed that administration of a loading dose was significantly associated with both CRA progression (P =0.031) and recurrence of CNV (P =0.020), whereas rs2010963 was not. CONCLUSIONS: These results suggest that the VEGF polymorphism influences the VA prognosis in highly myopic eyes with CNV within 1 year after anti-VEGF treatment. This association was still observed after removing its confounding effect through CNV size. The rs2010963 polymorphism was not associated with CNV recurrence or CRA progression, which indicates that these changes are not tied to intrinsic factors and may be controllable by improving treatment methods.
Authors: Masahiro Miyake; Kenji Yamashiro; Yasuharu Tabara; Kenji Suda; Satoshi Morooka; Hideo Nakanishi; Chiea-Chuen Khor; Peng Chen; Fan Qiao; Isao Nakata; Yumiko Akagi-Kurashige; Norimoto Gotoh; Akitaka Tsujikawa; Akira Meguro; Sentaro Kusuhara; Ozen Polasek; Caroline Hayward; Alan F Wright; Harry Campbell; Andrea J Richardson; Maria Schache; Masaki Takeuchi; David A Mackey; Alex W Hewitt; Gabriel Cuellar; Yi Shi; Luling Huang; Zhenglin Yang; Kim Hung Leung; Patrick Y P Kao; Maurice K H Yap; Shea Ping Yip; Muka Moriyama; Kyoko Ohno-Matsui; Nobuhisa Mizuki; Stuart MacGregor; Veronique Vitart; Tin Aung; Seang-Mei Saw; E-Shyong Tai; Tien Yin Wong; Ching-Yu Cheng; Paul N Baird; Ryo Yamada; Fumihiko Matsuda; Nagahisa Yoshimura Journal: Nat Commun Date: 2015-03-31 Impact factor: 14.919
Authors: David Blánquez-Martínez; Xando Díaz-Villamarín; Sonia García-Rodríguez; Alba Antúnez-Rodríguez; Ana Pozo-Agundo; Luis Javier Martínez-González; José Ignacio Muñoz-Ávila; Cristina Lucía Dávila-Fajardo Journal: Pharmaceutics Date: 2022-07-26 Impact factor: 6.525
Authors: Tien Y Wong; Kyoko Ohno-Matsui; Nicolas Leveziel; Frank G Holz; Timothy Y Lai; Hyeong Gon Yu; Paolo Lanzetta; Youxin Chen; Adnan Tufail Journal: Br J Ophthalmol Date: 2014-07-01 Impact factor: 4.638